Top Markets
#1 Islamic Coin Islamic Coin +154.27%
#2 PulseChain PulseChain +52.83%
#3 BOOK OF MEME BOOK OF MEME +44.89%
#4 DogBull DogBull +34.92%
#5 Nockchain Nockchain +18.68%
#6 ORDI ORDI +17.36%
#7 Ergo Ergo +17.32%
#8 rsERG rsERG +16.99%
#9 Bio Protocol Bio Protocol +16.75%
#10 PondCoin PondCoin +16.22%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM
Kedudukan dalam Saham #27177
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
Harga Saham
$1.10
Disegerakkan terakhir: 2026-08-19
Modal Pasaran
$34.64M
Perubahan (1 hari)
4.16%
Perubahan (1 tahun)
-32.68%
Negara
US
Perdagangan Actinium Pharmaceuticals, Inc. (ATNM)

Kategori

Healthcare
Pendapatan untuk Actinium Pharmaceuticals, Inc. (ATNM)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Actinium Pharmaceuticals, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Actinium Pharmaceuticals, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH